Status:
TERMINATED
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
Lead Sponsor:
Humanigen, Inc.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had an inad...
Eligibility Criteria
Inclusion
- At least 6 swollen and at least 6 tender joints
- C-reactive Protein (CRP) \> Upper Limit Normal (ULN)
- Prior inadequate response from biologic therapy
- Stable regimens of concomitant RA therapies
Exclusion
- Unstable medical conditions
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00995449
Start Date
January 1 2010
End Date
February 1 2012
Last Update
June 9 2014
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford, California, United States, 94304
2
Westlake Village, California, United States, 91361
3
Miami, Florida, United States, 33143
4
Honolulu, Hawaii, United States, 96813